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Abstract
Cutaneous cylindroma is an adnexal tumour with apocrine differentiation. A predisposition to multiple cylindromas
is seen in patients with Brooke–Spiegler syndrome, who carry germline mutations in the tumour suppressor gene
CYLD. Previous studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating
CYLD mutations as a recurrent driver mutation. We have previously shown that sporadic cylindromas express
either MYB–NFIB fusion transcripts or show evidence of MYB activation in the absence of such fusions. Here,
we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of
MYB activation. Strikingly, none of the inherited CYLD-defective (n = 23) tumours expressed MYB–NFIB fusion
transcripts. However, MYB expression was increased in the majority of tumours (69%) and global gene expression
analysis revealed that well-established MYB target genes were up-regulated in CYLD-defective tumours. Moreover,
knock-down of MYB expression caused a significant reduction in cylindroma cell proliferation, suggesting that
MYB is also a key player and oncogenic driver in inherited cylindromas. Taken together, our findings suggest
molecular heterogeneity in the pathogenesis of sporadic and inherited cutaneous cylindromas, with convergence
on MYB activation.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Recurrent gene fusions linking the oncogene MYB and
the transcription factor gene NFIB have been described
in the vast majority of adenoid cystic carcinomas
(ACCs) of the breast and head and neck [1–3]. The
MYB–NFIB oncoproteins retain the DNA-binding and
transactivation domains of MYB and likely drive an
oncogenic transcription programme [1]. The wild-type
MYB protein has an important role as a regulator of
stem/progenitor cells in the bone marrow and in colonic
crypts, and is overexpressed in several neoplasms,
including colon and breast carcinomas and subsets of T
cell acute lymphoblastic leukaemia [4].
Sporadic dermal cylindromas are cutaneous adnexal
tumours that occasionally share histological features
with ACC. Sporadic cylindromas express MYB–NFIB
fusion transcripts and protein at a lower frequency,
and occasionally demonstrate CYLD mutations
[5,6]. Multiple cylindromas are seen in patients with
Brooke–Spiegler syndrome (BSS), who carry germline
mutations in the tumour suppressor gene CYLD. These
patients develop cylindromas from puberty onwards,
typically on the head and neck. Interestingly, these
tumours show a striking architectural arrangement of
tumour cells, namely, a cylindrical pattern similar to that
seen in ACC. Spiradenomas that are both clinically and
histologically distinct in appearance have been shown
to grow in contiguity with cylindromas in BSS patients,
and hybrid lesions, called spiradenocylindromas, are
also a common feature [7]. Recent molecular character-
ization of these tumours highlighted the relative paucity
of genetic changes compared to other solid tumours.
These were limited to germline mutations in CYLD and
loss of heterozygosity at the CYLD locus [7]. Notably,
< 5% of patients with germline CYLD mutations who
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developmultiple cylindromas also developmembranous
basal cell adenomas (MBCA) of the salivary glands
[8]. MBCA, which accounts for 1–2% of all salivary
gland tumours in the general population, has striking
histological similarities with cylindroma [8].
We chose to explore the presence of MYB–NFIB
fusion transcripts in tumours from patients with
germline CYLD mutations, to determine whether
such fusions were present at a similar frequency to
that seen in sporadic cylindroma and ACC, which
share histological similarities. We found that inherited
cylindromas do not harbour MYB–NFIB gene fusions
but instead show frequent overexpression of MYB
mRNA and protein. Notably, we also show that MYB
drives the proliferation of CYLD-defective cylindroma
cells. Our findings highlight that different tumourigenic
events may ultimately converge on MYB, and that this
oncoprotein represents a putative therapeutic target in
sporadic and inherited cylindromas as well as in ACC.
Materials and methods
Tumour samples
Fresh-frozen (cases 1–13) and formalin-fixed, paraffin-
embedded (FFPE; cases 14–23) tumour tissues were
obtained from patients undergoing the surgery indicated
to control tumour burden or for symptomatic relief,
under regional ethical committee approval (Newcas-
tle upon Tyne, UK, Rec. Ref. 06/1001/59; and Pilsen,
Czech Republic, EC Approval date 13 December 2007).
Pertinent clinicopathological information and CYLD
mutation status of the 23 patient samples are shown in
Table 1; 10 patients and/or their samples have been a
subject of four previous studies [9–12].
RT–PCR and nucleotide sequence analysis
Total RNA was extracted from five 10 μm sections
obtained from fresh-frozen tumour specimens (cases
1–13), using the RNeasyMini-kit (Qiagen, Hilden, Ger-
many) and from five 10 μm FFPE sections from cases
14–23. The FFPE sections were deparaffinized and
RNA was isolated using the RNeasy FFPE Kit (Qia-
gen). All RNAs were subsequently converted to cDNA
using the SuperScript® First-Strand Synthesis System
(Invitrogen, Karlsruhe, Germany) with random hexamer
primers, as recommended by the manufacturer. As a
control for intact RNA and cDNA, RT–PCR reactions
for expression of UBC (amplification of a 150 bp prod-
uct), 18S (amplification of a 187 bp product) or GAPDH
(amplification of a 290 bp product) were performed on
all cDNAs.
All tumours were screened for the most common
MYB–NFIB fusion transcript variants, ie MYB exon
14 fused to NFIB exons 8a, 8c or 9, respectively, and
MYB exon 12 fused to NFIB exon 9. The MYB and
NFIB exons were numbered as described elsewhere
[1]. All PCR primers used are shown in Table S1 (see
supplementary material) or have been described pre-
viously [1]. As a positive control, two ACCs with
known MYB–NFIB fusion transcripts were used [1].
Each MYB–NFIB RT–PCR was repeated in triplicate.
Fluorescence in situ hybridization (FISH) analysis
FISH analysis for detection of MYB gene rearrange-
ments was performed on 5 μm FFPE sections, using a
dual-colourMYB split FISH probe (Abnova, Taipei City,
Taiwan). The protocols for pretreatment, hybridization
and post-hybridization washes were essentially as rec-
ommended by the manufacturer. Fluorescence signals
were digitized, processed and analysed using the Isis
FISH imaging system v. 5.5 (MetaSystems GmbH,
Altlussheim, Germany). At least 50 nuclei were scored
from each case.
Microarray data
Genome-wide transcriptomic profiles of 32 CYLD-
defective tumours were generated, using RNA extracted
from fresh-frozen microdissected tissues, as previously
described [7]. In brief, a bead microarray platform
was used to obtain the gene expression values from
32 tumour samples and 10 perilesional controls. Con-
trol tissue consisted of epidermis, hair follicles and
eccrine/apocrine glands. The Illumina WG-DASL plat-
form (San Diego, CA, USA; http://www.illumina.com)
allowed for monitoring of the gene expression of 24
526 transcripts; 50 ng total RNA from each sample was
converted to cDNA according to the supplied protocol
and then hybridized to Illumina Human 8v3 chips. A
confocal Illumina Infinium bead reader was used to
scan the chips and the signal values were extracted
using Illumina Beadstudio software v. 3.0. Microar-
ray data associated with this study are accessible at:
http://www.ebi.ac.uk (Accession No. E-MTAB-352).
Data normalization and analysis
Raw gene expression values were normalized using
quantile normalization. Differential expression analysis
was performed using Beadstudio software to detect sig-
nificant differentially expressed genes. Differences in
the signal values for each gene were scored with a dif-
ferential score (DS). Bonferroni testing was performed
to correct for multiple hypothesis testing, and the results
were ranked in order of differential score, with a differ-
ential score in the range +374 to −374, with± 65 corre-
sponding to a cut-off of p< 0.01 and± 13 corresponding
to p< 0.05.
Immunohistochemistry
FFPE tissue sections were dewaxed with xylene and
rehydrated in a graded ethanol series before under-
going microwave antigen retrieval in sodium citrate
buffer, pH 6.0. Tissue sections were blocked with perox-
idase blocking agent (Dako, Cambridgeshire, UK) and
then incubated with an anti-MYB antibody, ab17851
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Table 1. Clinicopathological and MYB–NFIB fusion data on 23 CYLD-defective tumours from 15 patients
Case no. Germline CYLD mutation Sex/age Diagnosis Tumour material
MYB–NFIB
fusion transcript
1# c.2460delC F/78 Cylindroma FF Negative
2 c.2806C> T F/63 Cylindroma FF Negative
3## c.2460delC F/42 Cylindroma FF Negative
4# c.2460delC F/78 Cylindroma FF Negative
5 c.2460delC F/58 Cylindroma FF Negative
6# c.2460delC F/78 Cylindroma FF Negative
7# c.2460delC F/78 Cylindroma FF Negative
8# c.2460delC F/78 Cylindroma FF Negative
9# c.2460delC F/78 Cylindroma FF Negative
10## c.2460delC F/42 Cylindroma FF Negative
11 c.2469+ 1 G>A F/85 Cylindroma FF Negative
12## c.2460delC F/42 Cylindroma FF Negative
13## c.2460delC F/42 Cylindroma FF Negative
14 Unknown
(Patient 55 in Grossmann et al. [9])
F/59 Cylindroma FFPE Negative*
15 c.2108G> C
(Patient 21 in Grossmann et al. [9])
M/34 Cylindroma FFPE Negative*
16 c.2806C> T
(Patient 48 in Grossmann et al. [9])
F/44 Cylindroma FFPE Negative*
17 c.2041+ 1 G> T
(Kacerovska et al. [10])
F/64 Cylindroma FFPE Negative*
18 Unknown** F53 Spiradeno-cylindroma FFPE Negative*
19 Large 13.6 kb deletion
(Patient 67 in Grossmann et al. [9])
F/47 Spiradeno-cylindroma FFPE Negative*
20 c.2108G> C
(Patient 22 in Grossmann et al. [9])
F/59 Spiradeno-cylindroma FFPE Negative*
21 Not performed
(Sister of patient 19)
F/33 Spiradenoma FFPE Negative*
22 Not performed
(Daughter of patient 20 in Kazakov et al. [11] who was
demonstrated to carry a heterozygous change in CYLD;
c.2806C> T)
F/51 Spiradenoma FFPE Negative*
23 c.1961 T>A
(Patient 18 in Grossmann et al. [9])
M/57 Spiradenoma FFPE Negative*
All tumours were negative for MYB–NFIB fusion transcripts by RT–PCR screening.
#Six tumours from the same patient.
##Four tumours from the same patient.
*No MYB rearrangements by FISH.
**Not done, but the patient had multiple tumours on the scalp.
FF, Fresh-frozen tumour tissue; FFPE, formalin-fixed. paraffin-embedded tumour tissue.
(Abcam, SPM 175). Tissue sections were thereafter
washed in phosphate-buffered saline (PBS) and probed
with secondary HRP-conjugated antibodies, and stain-
ing was visualized with 3,3′-diaminobenzidine (DAB).
Haematoxylin was used as a nuclear counterstain. The
samples were assessed for MYB positivity; if> 15% of
cells demonstrated increased expression of MYB, they
were considered positive.
Protein expression quantification
Five representative immunohistochemistry images were
taken from each tumour sample and control areas using
a Zeiss Axioimager (Zeiss, UK). ImageJ software (v.
1.48 g; http://imagej.nih.gov/ij) was used to quantify
DAB staining. RGB values that were restricted to the
colour of DAB in our staining protocol were used to
select for areas in images that were DAB-positive. The
area of the positive image was then quantified and com-
pared to the total area assessed to generate a ratio of
positive staining. Themean of the ratios was used to gen-
erate a ratio per sample. The values in the tumours were
then compared with the values in the controls, using a
t-test.
Cylindroma cell culture and siRNA transfection
Primary CYLD-defective cylindroma cells were derived
from BSS patients as previously described [7], and
were propagated in keratinocyte–SFM medium sup-
plemented with penicillin (100 U/ml) and streptomycin
(100 μg/ml) (Thermo Fischer Scientific) at 37 ∘C and
5% CO2 in 12.5 cm
2 flasks (BD Falcon), or in assay
plates (see below) coated using a Coating Matrix Kit
(Thermo Fischer Scientific). Cylindroma cells were
subsequently transfected with 50 nM Stealth MYB siR-
NAs (HSS106819 and HSS106821) or negative control
siRNAs, using the Lipofectamine RNAiMAX trans-
fection reagent (all from Thermo Fisher Scientific) in
antibiotic-free medium, according to the manufacturer’s
instructions.
Reverse-transcription quantitative RT–PCR
(RT–qPCR)
CYLD-defective cylindroma cells were treated with
MYB siRNAs for 48 h before total RNA was extracted
using an RNeasy Micro-kit (Qiagen). RNA was
reverse-transcribed using an iScript cDNA Synthesis
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Kit (Bio-Rad Laboratories) and quantitative real-time
PCR (qPCR) analysis was performed using the AB
7500 Fast Real-time PCR System (Thermo Fisher Sci-
entific) with TaqMan Gene Expression Assays (Thermo
Fisher Scientific) for MYB (Hs00920554_m1), BCL2
(Hs00608023_m1) and BIRC3 (Hs00154109_m1), and
GUSB (Hs99999908_m1) as a reference gene. The
relative expression levels of the genes were calculated
using the ΔΔCT method [13].
Western blotting
CYLD-defective cylindroma cells were treated with
MYB siRNAs for 72 h, after which total cellular pro-
tein was prepared by lysing cells in RIPA lysis buffer
(Millipore) supplemented with complete Mini Pro-
tease Inhibitors (Roche). Protein concentrations in
lysates were determined using a DC Protein Assay
Kit (Bio-Rad Laboratories). Protein samples were
diluted for equal loading and analysed by western
blotting, using the NuPage system (Life Technolo-
gies) on 4–12% Bis-Tris gels. Proteins were blotted
onto PVDF membranes and probed with mouse
monoclonal antibodies for MYB (1–1, Merck Mil-
lipore) and β-actin (ab8227, Abcam). Bands were
visualized using horseradish peroxidase-conjugated
secondary antibodies by chemiluminescent detection
with a SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific), and subse-
quently imaged using a LAS-4000 imaging system
(Fujifilm).
Cell proliferation assay
CYLD-defective cylindroma cells were treated with
MYB siRNAs for 6 consecutive days, after which cell
proliferation was assayed using Alamar Blue Reagent
(Thermo Fisher Scientific) and a VICTOR-3 multilabel
reader (Perkin-Elmer), according to instructions sup-
plied by the manufacturers.
Results
CYLD-defective tumours do not express MYB–NFIB
fusion transcripts
To determine whether inherited, CYLD-defective
tumours express MYB–NFIB fusion transcripts, we
adopted a validated RT–PCR strategy for exploring
the presence of such transcripts in a collection of
13 snap-frozen and 10 FFPE tumours derived from
patients with BSS with confirmed CYLD mutations.
The mean age of the patients was 55.9 years and the
tumours (n= 23) were from 15 patients (13 females
and two males) from 11 genetically-defined families
(Table 1). None of the tumour samples expressed any
of the MYB–NFIB fusion transcript variants tested
for (data not shown). In contrast, the positive controls
from fusion-positive ACCs expressed the expected
MYB–NFIB fusion transcript variants (data not shown).
To identify possible rearrangements of the MYB
locus, we performed FISH analysis of FFPE sections
from 10 CYLD-defective tumours (cases 14–23).
Using a dual-colour MYB break-apart probe, we did
not detect any evidence of rearrangements or copy
number gains/amplifications involving the MYB locus
(Figure 1).
MYB protein expression is up-regulated in inherited
CYLD-defective tumours
We assessed MYB protein expression in inherited
CYLD-defective tumours (n= 16) to determine the
frequency of MYB-positive tumours in this group.
These tumours included cylindromas and spiradeno-
mas from patients with germline mutations in CYLD.
Tissue sections were probed with anti-MYB anti-
body and protein expression was visualized using
immunohistochemistry (Figure 2A, B). Eleven of 16
tumour samples (69%) were MYB-positive, ie they
showed> 15% positive cells (Figure 2C). MYB protein
expression in cylindromas (Figure 2A) and spirade-
nomas (Figure 2B) demonstrated nuclear localization
(white arrows in inset) and increased intensity of
staining when compared to perilesional tissues (see sup-
plementary material, Figures S1A, S2). Immunopositive
cylindroma cells were seen in parts of each island, and
were not restricted to the basal cells. In MYB-positive
spiradenomas, the expression was also variable in
intensity, with positive cells scattered throughout
the specimens (see supplementary material, Figure
S1B). Similar MYB staining patterns were seen in
MYB–NFIB fusion-positive and -negative sporadic
cylindromas (see supplementary material, Figure S1C,
D). Semi-quantitative assessment of protein expression
by measurement of immunostaining intensity, using
ImageJ software, showed this difference in expression
between tumour and control skin to be statistically sig-
nificant when compared to adjacent normal epidermis
(Figure 2D).
Inherited CYLD-defective tumours demonstrate a
MYB gene expression signature
We explored the expression of MYB and selected MYB
target genes following their curation from the published
literature and previous experimental data from 32
CYLD-defective tumours [7], in a dataset derived from
microarray gene expression studies (no. of transcripts in
this set= 263). Genes that were differentially expressed
in the pooled signature of 32 CYLD-defective tumours
compared to 10 control skin samples, with a threshold
for statistical significance of p< 0.05 after correction
for multiple hypothesis testing, were included (n= 48).
To visualize the expression of each of these genes at
an individual sample level, normalized signal values
were plotted on a heat map, following logarithmic
transformation (Figure 3). The tumours highlighted the
overexpression ofMYB (fold-change increase=×2.04),
BCL2 (fold-change increase=×2.34) and BIRC3
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Figure 1. (A, B) FISH analysis of two inherited cylindromas, showing two non-rearranged copies ofMYB in each cell nucleus (fused red/green
signals indicated by arrows). (C) FISH analysis of a MYB–NFIB fusion-positive adenoid cystic carcinoma (control) with a split MYB signal
consistent with a MYB gene fusion; arrows, separated red and green signals; arrowhead, intact MYB allele
Figure 2. MYB protein expression in inherited CYLD-defective tumours. FFPE tissue sections of cylindromas and spiradenomas (n= 16)
and perilesional control skin were immunostained with an anti-MYB antibody. (A, B) MYB protein expression in (A) cylindromas and (B)
spiradenomas, demonstrating nuclear localization (black arrows in inset) and increased intensity of staining when compared to perilesional
tissue; scale bars= 50 μm. (C) Of the cases, 69% (11/16) were positive for MYB. (D) Protein expression of MYB was significantly increased
in cylindromas and spiradenomas compared to controls
(fold-change increase=×3.93) (Table 2). Notably,
siRNA knock-down of MYB in cylindroma cells
resulted in down-regulation of both BCL2 and BIRC3
mRNA levels (see supplementary material, Figure
S3). Some genes, such as CD34, that have been
described as MYB target genes in ACC [4] were,
however, found to be underexpressed in cylindroma
(fold change decrease=×0.47), whilst genes such as
MAD1L1 were not differentially expressed between
tumours and controls (data not shown). Clustering by
Euclidean distance separated the majority of cylin-
dromas and spiradenomas (n= 30) from the control
tissue, apart from two trichoepitheliomas (tumours
1 and 30).
MYB promotes the proliferation of CYLD-defective
cylindroma cells
To investigate the biological significance of MYB over-
expression in cylindroma, given the lack ofMYB–NFIB
fusion transcripts, we used siRNAs to knock downMYB
mRNA expression in cultured primary CYLD-defective
cylindroma cells. Cells from three different primary
tumours from two patients undergoing surgical excision,
who carried germline mutations in CYLD (c.2460delc),
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Figure 3. MYB target genes are overexpressed in CYLD-defective tumours. A heat map plot illustrating the expression levels of MYB and
its known target genes in 32 CYLD-defective tumours and 10 controls. MYB target genes and signalling pathway members that were
differentially expressed (p< 0.05) across an average of 32 tumours compared to an average of 10 controls (tumours and controls are
indicated at the bottom of the heat map) were included, and transcript expression levels at a single sample level are illustrated in the
heat map; red, overexpressed transcripts; blue, transcripts that were under-expressed; gene names indicated on the right-hand side of the
figure; where data from multiple transcripts for a single gene were available, these are indicated with a numerical suffix (n= 8). Clustering
by similarity is shown, as determined by Euclidean distance
were used. Knock-down ofMYBmRNA and protein lev-
els (Figure 4A, B) led to a significant decrease in cell
proliferation of cylindroma cells in three independent
experiments (Figure 4C). These results provide further
evidence that MYB is involved in the regulation of cell
proliferation of CYLD-defective cylindromas.
Discussion
We recently reported the presence ofMYB–NFIB fusion
transcripts in sporadic dermal cylindromas [6]. Whilst
55% of the tumours were fusion-positive, some tumours
(12%) demonstrated MYB activation despite the lack of
fusion transcripts. These results suggest that MYB acti-
vation can replace MYB–NFIB fusions in the patho-
genesis of a subset of sporadic dermal cylindromas.
Similar observations have been made in ACC, where
the majority of tumours are MYB–NFIB-positive and
a smaller proportion of tumours have MYB activa-
tion by other mechanisms, such as gene duplication
[2,14]. Here, we demonstrate thatMYB activation is also
frequently seen in inherited cylindromas, but strikingly
there was a lack ofMYB–NFIB fusion transcripts in the
23 tumour samples studied. Similarly, we did not find
any evidence of rearrangements or gain/amplification
of the MYB locus in the 10 tumours studied. The find-
ing of MYB activation in these inherited tumours is
intriguing, since the underlying mechanism behind for-
mation of inherited cylindromas has been shown to be
largely limited to a germline mutation of CYLD and
loss of heterozygosity at the CYLD locus. This results
in increased NF-κB signalling, as CYLD is involved
in the negative regulation of this oncogenic signalling
pathway at several steps, including TRAF2, TRAF6,
TAK1 and BCL3 [15]. Since MYB is a recognised
NF-κB target gene [16] and has NF-κB binding sites
within its promoter (http://bioinfo.lifl.fr/NF-KB/), it is
tempting to speculate that MYB might be activated in
a subset of inherited cylindromas as a consequence of
aberrant NF-κB signalling, due to loss of CYLD func-
tion. In line with this reasoning, it will be interesting
to study whether NF-κB inhibitors can down-regulate
MYB and inhibit the proliferation of CYLD-defective
cylindroma cells. Preliminary work with primary cul-
tures of inherited cylindromas demonstrate variable
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Table 2. MYB target genes are up-regulated in CYLD-defective tumours
Gene expression data from 32 cylindroma tumours and 10 control perilesional skin samples were pooled into tumour and control groups. Differentially expressed genes
with a threshold of p< 0.05 were included and the fold changes (FC) are indicated for the respective transcripts: red, genes that are overexpressed in CYLD-defective
tumours compared to control skin; blue, genes that are reduced in expression in CYLD-defective tumours compared to control skin. Where more than one transcript
mapped to a gene, the transcript with the highest value is shown.
responses, but no down-regulation of MYB after NF-κB
inhibition, suggesting that a variety of mechanisms may
be at play (Rajan et al. unpublished data). However, in
MYB–NFIB-positive ACC cells, NF-κB inhibitors have
no effect on MYB activation (Andersson et al., unpub-
lished data).
The occurrence of MYB–NFIB fusion transcripts in
sporadic cylindromas and their absence in inherited
cases may reflect the timing of a gainedMYB activation
state. In patients with germline mutations in CYLD, the
typical age of presentation of the first tumour is 16 years
[17]. In these patients, loss of heterozygosity (LOH) at
the CYLD locus is seen in 76% of tumours [18], and
some of the remaining cases have compound heterozy-
gous changes affecting CYLD [5]. By contrast, sporadic
cylindromas typically present beyond the fifth decade
of life. STR studies have highlighted that approximately
50% of these tumours (n= 14) demonstrate LOH at
16q, the locus of CYLD [18], making the recent finding
that 55% of tumours in a similar sized study (n= 12)
demonstrate MYB–NFIB fusions of interest [6]. There
are limited data on the sequencing of coding exons of
sporadic cylindromas, but some have indeed been shown
to carry mutations in CYLD [5]. However, it remains
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Figure 4. MYB promotes cell proliferation of CYLD-defective cylindroma cells. (A) RT–qPCR analysis of MYB mRNA expression in cultured
cells from case 1, following 48 h ofMYB siRNA treatment; **p< 0.01, ***p< 0.001. (B) Western blot analysis of MYB protein expression in case
1 after 72 h of MYB siRNA treatment. (C) Effects ofMYB siRNA treatment (6 days) on the proliferation of cultured, primary cylindroma cells
from three individual tumours (cases 1, 3A and 3B); ***p< 0.001. Representative data are shown from one of three independent experiments
to be determined whether MYB–NFIB fusion-positive
sporadic dermal cylindromas also carry bi-allelic CYLD
mutations, as these two changes could potentially act
synergistically in promoting cylindroma development.
To further examine the role of MYB overexpression
in the molecular pathogenesis of inherited cylindromas,
we silenced the expression of MYB in CYLD-defective
cylindroma cells, using RNA interference. This resulted
in a significant inhibition of MYB target genes and
proliferation of cylindroma cells from three indepen-
dent tumours, suggesting thatMYB activation drives the
growth of CYLD-defective cylindromas and potentially
also the growth of MYB–NFIB-positive sporadic cylin-
dromas. This is in line with previous studies of Cyld−/−
mice, which do not spontaneously develop tumours
but are highly susceptible to chemically induced skin
tumours [19], indicating that additional molecular
events besides Cyld inactivation are required for tumour
formation.
Interestingly, parallels between inherited cylindromas
and ACC may extend beyond MYB, as was recently
highlighted with the demonstration that both tumour
types overexpress TRKC [7,20]. CYLD-mutation car-
riers also develop salivary gland tumours, and there
are reports of areas of ACC-like differentiation arising
within cylindromas [21]. Furthermore, recent studies of
the mutational landscape in ACC have shown thatCYLD
is mutated in 4% of these tumours [22]. It is also intrigu-
ing that MYB–NFIB fusions are seen in ACCs of the
breast and salivary glands as well as in sporadic cylin-
dromas, suggesting that MYB activation may be central
to the histological patterning of these tumours. Our data
highlight the potential cross-cutting insights that can be
obtained from the study of these rare tumours. MYB is
an attractive therapeutic target in ACC and treatments
that are developed for ACC may hence be of relevance
for patients with both sporadic and inherited cylindro-
mas, and vice versa.
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